SPOTLIGHT -
Revumenib Drives Durable CR/CRh Rates in KMT2A-rearranged and NMP1-mutant AML
Rosenthal Discusses the Need for Standardized Care in AYA Hodgkin Lymphoma
Remestemcel-L BLA Resubmitted to FDA for Pediatric Steroid-Refractory aGVHD
Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL
NICE Recommends Axicabtagene Ciloleucel for Lymphoma
Magrolimab Plus Rituximab/Chemo Elicits Deep Responses in Relapsed/Refractory DLBCL
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
